Cargando…

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

Mostrar otras versiones (1)

SARS-CoV-2 is a betacoronavirus virus responsible for the COVID-19 pandemic. Here, we determined the X-ray crystal structure of a potent neutralizing monoclonal antibody, CV30, isolated from a patient infected with SARS-CoV-2, in complex with the receptor binding domain (RBD). The structure reveals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurlburt, Nicholas K., Wan, Yu-Hsin, Stuart, Andrew B., Feng, Junli, McGuire, Andrew T., Stamatatos, Leonidas, Pancera, Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301900/ https://www.ncbi.nlm.nih.gov/pubmed/32577631 http://dx.doi.org/10.1101/2020.06.12.148692

Ejemplares similares

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
por: Hurlburt, Nicholas K., et al.
Publicado: (2020)

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation
por: Seydoux, Emilie, et al.
Publicado: (2020)

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual
por: Seydoux, Emilie, et al.
Publicado: (2020)

Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization
por: Ding, Shilei, et al.
Publicado: (2020)

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
por: Hurlburt, Nicholas K., et al.
Publicado: (2022)

Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
por: Jennewein, Madeleine F., et al.
Publicado: (2021)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
por: Seydoux, Emilie, et al.
Publicado: (2021)

Structural basis for germline antibody recognition of HIV-1 immunogens
por: Scharf, Louise, et al.
Publicado: (2016)

Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes
por: Bancroft, Tara, et al.
Publicado: (2019)

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
por: Parks, K. Rachael, et al.
Publicado: (2019)

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
por: Stamatatos, Leonidas, et al.
Publicado: (2021)

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies
por: McGuire, Andrew T., et al.
Publicado: (2013)

A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
por: Stamatatos, Leonidas, et al.
Publicado: (2021)

Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies
por: Briney, Bryan, et al.
Publicado: (2016)

Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies
por: Hu, Wei-Gang, et al.
Publicado: (2013)

Structural basis of epitope selectivity and potent protection from malaria by PfCSP antibody L9
por: Martin, Gregory M., et al.
Publicado: (2023)

Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus
por: Singh, Swati, et al.
Publicado: (2020)

Structural basis for neutralization of an anicteric hepatitis associated echovirus by a potent neutralizing antibody
por: Feng, Rui, et al.
Publicado: (2021)

Anti-idiotypic antibodies elicit anti-HIV-1–specific B cell responses
por: Dosenovic, Pia, et al.
Publicado: (2019)

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice
por: McGuire, Andrew T., et al.
Publicado: (2016)

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
por: Wrapp, Daniel, et al.
Publicado: (2020)

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
por: Wrapp, Daniel, et al.
Publicado: (2020)

Evolution of Cross-Neutralizing Antibody Specificities to the CD4-BS and the Carbohydrate Cloak of the HIV Env in an HIV-1-Infected Subject
por: Mikell, Iliyana, et al.
Publicado: (2012)

Molecular Signatures of Hemagglutinin Stem-Directed Heterosubtypic Human Neutralizing Antibodies against Influenza A Viruses
por: Avnir, Yuval, et al.
Publicado: (2014)

Insights into the Structural Basis of Antibody Affinity Maturation from Next-Generation Sequencing
por: Mishra, Arjun K., et al.
Publicado: (2018)

Multiscale affinity maturation simulations to elicit broadly neutralizing antibodies against HIV
por: Conti, Simone, et al.
Publicado: (2022)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2018)

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core
por: Borst, Andrew J, et al.
Publicado: (2018)

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
por: Muecksch, Frauke, et al.
Publicado: (2021)

Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies
por: Carbonetti, Sara, et al.
Publicado: (2014)

Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
por: Rouet, Romain, et al.
Publicado: (2021)

Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1
por: Mikell, Iliyana, et al.
Publicado: (2011)

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
por: Lv, Zhe, et al.
Publicado: (2020)

Mechanistic basis for potent neutralization of Sin Nombre hantavirus by a human monoclonal antibody
por: Stass, Robert, et al.
Publicado: (2023)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Correction: Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1
por: Mikell, Iliyana, et al.
Publicado: (2011)

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
por: Yan, Renhong, et al.
Publicado: (2021)

Development of a potent high-affinity human therapeutic antibody via novel application of recombination signal sequence–based affinity maturation
por: Kielczewska, Agnieszka, et al.
Publicado: (2021)

Potent Dengue Virus Neutralization by a Therapeutic Antibody with Low Monovalent Affinity Requires Bivalent Engagement
por: Edeling, Melissa A., et al.
Publicado: (2014)

Structural basis for broad coronavirus neutralization
por: Sauer, Maximilian M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8bga48ug2odbfru36h8g2uoque